Alto Neuroscience (ANRO) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Alto Neuroscience is set to release its Q2 2025 earnings on August 12, with an expected loss of ($0.57) per share.
• The company's shares recently traded at $3.07, with a market capitalization of $83.10 million and a P/E ratio of -1.31.
• Analysts currently have a consensus rating of "Moderate Buy" for Alto Neuroscience, with a target price of $8.50.

Alto Neuroscience (NYSE:ANRO - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Tuesday, August 12th. Analysts expect Alto Neuroscience to post earnings of ($0.57) per share for the quarter.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.06. On average, analysts expect Alto Neuroscience to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alto Neuroscience Price Performance

Shares of NYSE ANRO traded down $0.04 during trading on Thursday, reaching $3.06. The company had a trading volume of 98,695 shares, compared to its average volume of 118,048. Alto Neuroscience has a 52 week low of $1.60 and a 52 week high of $15.04. The business's 50 day moving average price is $2.63 and its 200-day moving average price is $2.81. The stock has a market cap of $82.83 million, a PE ratio of -1.31 and a beta of 1.84. The company has a debt-to-equity ratio of 0.15, a quick ratio of 22.53 and a current ratio of 22.53.

Analysts Set New Price Targets

ANRO has been the subject of several research analyst reports. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Alto Neuroscience in a research report on Thursday, June 26th. Wedbush reissued a "neutral" rating and issued a $4.00 target price on shares of Alto Neuroscience in a research note on Thursday, May 15th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.50.

Institutional Investors Weigh In On Alto Neuroscience

A hedge fund recently bought a new stake in Alto Neuroscience stock. AQR Capital Management LLC purchased a new stake in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 24,099 shares of the company's stock, valued at approximately $52,000. AQR Capital Management LLC owned 0.09% of Alto Neuroscience as of its most recent SEC filing.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.